股本结构
单位：万股
| 公告日期 | 2026-10-06 | 2026-08-28 | 2026-08-28 | 2026-09-10 | 2026-05-14 | 2026-05-14 |
|---|---|---|---|---|---|---|
| 证券总股本 | 1261.13 | 1234.47 | 1114.47 | 1082.43 | 1078.95 | 1043.08 |
| 普通股本 | 1261.13 | 1234.47 | 1114.47 | 1082.43 | 1078.95 | 1043.08 |
| 优先股 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2026-10-05 | 2026-08-28 | 2026-08-27 | 2026-06-30 | 2026-05-13 | 2026-03-31 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2026-10-06 | 1261.13 | 未披露 | 定期报告 | 2026-10-05 |
| 2026-08-28 | 1234.47 | 未披露 |
更多>>
Common stock offered 1,200,000 shares by the company
|
2026-08-28 |
| 2026-08-28 | 1114.47 | 未披露 | 定期报告 | 2026-08-27 |
| 2026-09-10 | 1082.43 | 未披露 |
更多>>
From July 1,2025 to June 30,2026
Exercise of pre-funded warrants
Issuance of common shares, the First Common Warrants and the Second Common Warrants related to the First Offering and the Second Offering (each as defined below), net of issuance costs of $6
Issuance of common shares under the Sales Agreement (as defined below) with Alliance Global Partners, or AGP, net of issuance costs of $59
Share-based compensation to employees, directors, and non-employee consultants
|
2026-06-30 |
| 2026-05-14 | 1078.95 | 未披露 | 定期报告 | 2026-05-13 |
| 2026-04-23 | 1077.47 | 未披露 | 定期报告 | 2026-04-23 |
| 2026-05-14 | 1043.08 | 未披露 |
更多>>
From January 1, 2026 to March 31, 2026
Share-based compensation to employees, directors, and non-employee consultants
Issuance of common shares and Second Common Warrants related to the Second Offering , net of issuance costs of $3 and Issuance of common shares under the Sales Agreement with A.G.P
|
2026-03-31 |
| 2026-02-12 | 1005.07 | 未披露 | 定期报告 | 2026-02-11 |
| 2026-02-12 | 997.78 | 未披露 |
更多>>
From October 1, 2025 to December 31, 2025
Share-based compensation to employees, directors, and non-employee consultants
Issuance of common shares and Common Warrants related to the Offering (as defined below), net of issuance costs of $3
Issuance of common shares under a sales agreement with A.G.P, (as defined below), net of issuance costs of $43
Exercise of pre-funded warrants
|
2025-12-31 |
| 2025-12-09 | 987.89 | 未披露 |
更多>>
Common Stock offered 625,000 shares by the company
|
2025-12-15 |
| 2025-11-12 | 925.39 | 未披露 | 定期报告 | 2025-11-11 |
| 2025-11-12 | 816.27 | 未披露 |
更多>>
From July 1, 2025 to September 30, 2025
Share-based compensation to employees, directors, and non-employee consultants
|
2025-09-30 |
| 2025-09-17 | 815.59 | 未披露 | 定期报告 | 2025-09-16 |
| 2025-09-17 | 789.38 | 未披露 |
更多>>
From July 1, 2024 to June 30, 2025
Share-based compensation to employees, directors, and non-employee consultants
Issuance of common shares and warrants related to February 2025 offering, net of issuance costs of $420
Issuance of common shares related to Kokomodo Transaction (defined below), net of issuance costs of $47
|
2025-06-30 |
| 2025-05-27 | 787.12 | 未披露 | 定期报告 | 2025-05-27 |
| 2025-05-13 | 783.26 | 未披露 | 定期报告 | 2025-05-12 |
| 2025-05-13 | 777.54 | 未披露 |
更多>>
From January 1, 2025 to March 31, 2025
Issuance of common shares and warrants, net of issuance costs of $476
Share-based compensation to employees, directors, and non-employee consultants
|
2025-03-31 |
| 2025-02-11 | 699.71 | 未披露 | 定期报告 | 2025-02-10 |
| 2025-02-11 | 556.54 | 未披露 |
更多>>
From October 1, 2024 to December 31, 2024
Share-based compensation to employees, directors, and non-employee consultants
|
2024-12-31 |
| 2024-11-12 | 555.87 | 未披露 | 定期报告 | 2024-11-11 |
| 2024-11-12 | 550.73 | 未披露 |
更多>>
From July 1, 2024 to September 30,2024
Share-based compensation to employees, directors, and non-employee consultants
|
2024-09-30 |
| 2024-09-18 | 547.02 | 未披露 | 定期报告 | 2024-09-13 |
| 2024-09-18 | 540.82 | 未披露 |
更多>>
From July 1, 2023 to June 30, 2024
Share-based compensation to employees, directors, and non-employee consultants
Issuance of common shares under a sales agreement with A.G.P, net of issuance
Round-up of shares due to reverse share split effectuated on April 1, 2024
|
2024-06-30 |
| 2024-05-01 | 538.88 | 未披露 | 定期报告 | 2024-05-01 |
| 2024-03-27 | 522.71 | 未披露 |
更多>>
Pluri Inc. announced that a reverse share split of the Company’s issued and outstanding common shares, par value $0.00001 per share at a ratio of 1-for-8 is expected to be implemented at market open on April 1, 2024.
|
2024-04-01 |
| 2024-03-27 | 4181.70 | 未披露 | 定期报告 | 2024-03-27 |
| 2024-02-12 | 4148.02 | 未披露 | 定期报告 | 2024-02-12 |
| 2024-02-12 | 4168.00 | 未披露 |
更多>>
From October 1, 2023 to December 31, 2023
Share-based compensation to employees, directors, and non-employee consultants
|
2023-12-31 |
| 2023-11-13 | 4148.02 | 未披露 | 定期报告 | 2023-11-13 |
| 2023-11-13 | 4144.85 | 未披露 |
更多>>
From July 1, 2023 to September 30, 2023
Share-based compensation to employees, directors, and non-employee consultants
|
2023-09-30 |
| 2023-09-12 | 4135.19 | 未披露 | 定期报告 | 2023-09-08 |
| 2023-09-12 | 4124.55 | 未披露 |
更多>>
From July 1, 2022 to June 30, 2023
Share-based compensation to employees, directors, and non-employee consultants
Issuance of common shares and warrants, net of issuance costs of $445
|
2023-06-30 |
| 2023-06-01 | 4112.09 | 未披露 | 定期报告 | 2023-05-26 |
| 2023-05-09 | 4111.84 | 未披露 | 定期报告 | 2023-05-09 |
| 2023-05-09 | 4107.22 | 未披露 |
更多>>
From January 1, 2023 to March 31, 2023
Share-based compensation to employees, directors, and non-employee consultants
Issuance of common shares and warrants related to December 2022 Private Placement, net of issuance costs of $74
|
2023-03-31 |
| 2023-02-27 | 4084.84 | 未披露 | 定期报告 | 2023-02-27 |
| 2023-02-13 | 3980.72 | 未披露 | 定期报告 | 2023-02-13 |
| 2023-02-13 | 3829.12 | 未披露 |
更多>>
From October 1, 2022 to December 31, 2022
Share-based compensation to employees, directors, and non-employee consultants
Issuance of common stock and warrants related to December 2022 Private Placement, net of issuance costs of $361
|
2022-12-31 |
| 2022-11-10 | 3265.72 | 未披露 | 定期报告 | 2022-11-08 |
| 2022-11-10 | 3263.47 | 未披露 |
更多>>
From July 1, 2022 to September 30, 2022
Share-based compensation to employees, directors, and non-employee consultants
|
2022-09-30 |
| 2022-09-21 | 3262.03 | 未披露 | 定期报告 | 2022-09-15 |
| 2022-09-21 | 3250.75 | 未披露 |
更多>>
From July 1, 2021 to June 30, 2022
Share-based compensation to employees, directors and non-employee consultants
Issuance of common shares under Open Market Sales Agreement, net of issuance costs of 380,000
Issuance of common shares related to February 2021 registered direct offering net of issuance costs of 1,923,000
Exercise of options by employees and non-employee consultants
Exercise of warrants by investors
|
2022-06-30 |
| 2022-04-27 | 3234.76 | 未披露 | 定期报告 | 2022-04-18 |
| 2022-05-09 | 3234.24 | 未披露 |
更多>>
From July 1, 2021 to March 31, 2022
Share-based compensation to employees, directors, and non-employee consultants
|
2022-03-31 |
| 2022-02-07 | 3223.28 | 未披露 | 定期报告 | 2022-02-04 |
| 2022-02-07 | 3222.51 | 未披露 |
更多>>
From July 1, 2021 to December 31, 2021
Share-based compensation to employees, directors, and non-employee consultants
|
2021-12-31 |
| 2021-11-08 | 3209.96 | 未披露 | 定期报告 | 2021-11-04 |
| 2021-11-08 | 3209.69 | 未披露 |
更多>>
From July 1, 2021 to September 30, 2021
Share-based compensation to employees, directors, and non-employee consultants
|
2021-09-30 |
| 2021-09-13 | 3200.48 | 未披露 | 定期报告 | 2021-09-03 |
| 2021-09-13 | 3195.78 | 未披露 |
更多>>
From July 1, 2020 to June 30, 2021
Share-based compensation to employees, directors and non-employee consultants
Issuance of common shares under ATM Agreement, net of issuance costs of $380
Issuance of common shares related to February 2021 registered direct offering net of issuance costs of $1,923
Exercise of options by employees and non-employee consultants
Exercise of warrants by investors
|
2021-06-30 |
| 2021-05-06 | 3174.02 | 未披露 |
更多>>
From January 1, 2021 to March 31, 2021
Share-based compensation to employees, directors and non-employee consultants
Issuance of common Share under New ATM Agreement, net of issuance costs of $151
Issuance of common shares related to February 2021 registered direct offering net of issuance costs of 1,923$
|
2021-03-31 |
| 2021-04-08 | 3169.32 | 未披露 | 定期报告 | 2021-03-21 |
| 2021-02-04 | 3152.93 | 未披露 |
更多>>
1.Common stock offered by the company 4,761,905 shares.
2.Unless otherwise indicated, all information in this prospectus supplement is based on 26,767,362 shares of common stock outstanding as of January 31, 2021.
|
2021-02-04 |
| 2021-02-03 | 2676.74 | 未披露 | 定期报告 | 2021-01-31 |
| 2021-02-08 | 2583.93 | 未披露 |
更多>>
From October 1,2020 to December 31,2020
Share-based compensation to employees, directors and non-employee consultants
Issuance of common Share under New ATM Agreement, net of issuance costs of $151
Exercise of warrants
Exercise of options by employees and non-employee consultants
|
2020-12-31 |
| 2020-11-05 | 2563.34 | 未披露 | 定期报告 | 2020-11-03 |
| 2020-11-05 | 2561.28 | 未披露 |
更多>>
From July 1, 2020 to September 30, 2020
Stock-based compensation to employees,directors and non-employee consultant
Issuance of common stock under Open Market Sales Agreement,net of issuance costs of $198
Exercise of options by non-employee consultants
Round up of shares due to reverse stock split effectuated on July 25, 2019
|
2020-09-30 |
| 2020-09-10 | 2555.47 | 未披露 | 定期报告 | 2020-09-04 |
| 2020-09-10 | 2549.27 | 未披露 |
更多>>
From July 1, 2019 to June 30, 2020
Stock-based compensation to employees, directors and non-employee consultants
Issuance of common stock under Open Market Sales Agreement, net of aggregate issuance costs of $3,573
Issuance of common stock related to May 2020 registered direct offering, net of issuance costs of $99
Exercise of options by employees and non-employee consultants
Exercise of warrants by investors
Round up of shares due to reverse stock split effectuated on July 25, 2019
|
2020-06-30 |
| 2020-05-07 | 2490.69 | 未披露 |
更多>>
1.Common stock offered by us 1,587,302 shares
2.based on 16,934,417 shares of common stock outstanding as of December 31, 2019
|
2020-05-07 |
| 2020-05-11 | 1867.32 | 未披露 |
更多>>
From January 1, 2020 to March 31, 2020
Stock-based compensation to employees, directors and non-employee consultants
Issuance of common stock under Open Market Sales Agreement, net of issuance costs of $792
|
2020-03-31 |
| 2020-02-06 | 1786.15 | 未披露 | 定期报告 | 2020-02-01 |
| 2020-02-06 | 1693.44 | 未披露 |
更多>>
from October 1, 2019 to December 31, 2019
Stock-based compensation to employees, directors and non-employee consultants
Issuance of common stock under Open Market Sales Agreement, net of issuance costs of $614
Exercise of options by employees and non-employee consultants
Net loss
|
2019-12-31 |
| 2019-11-07 | 1571.16 | 未披露 | 定期报告 | 2019-11-01 |
| 2019-11-07 | 1561.99 | 未披露 |
更多>>
from July 1, 2019 to September 30, 2019
Stock-based compensation to employees, directors and non-employee consultants
Issuance of common stock under Open Market Sales Agreement, net of issuance costs of $198
Exercise of options by employees and non-employee consultants
Round up of shares due to reverse stock split effectuated on July 25, 2019
|
2019-09-30 |
| 2019-09-12 | 1554.76 | 未披露 | 定期报告 | 2019-09-04 |
| 2019-07-25 | 1531.23 | 未披露 |
更多>>
Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced that, its Board of Directors has approved a 1-for-10 reverse split of the Company's (a) authorized shares of common stock; and (b) issued and outstanding shares of common stock. The reverse split will be effective as of market open on July 25, 2019 on Nasdaq. The reverse split will result in each outstanding ten pre-split shares of common stock automatically combining into one new share of common stock without any action on the part of the shareholders. As of July 24, 2019 (immediately prior to the Effective Date), there were 153,122,520 shares of common stock outstanding. As a result of the Reverse Split, there are approximately 15,312,252 shares of common stock outstanding (subject to adjustment due to the effect of rounding fractional shares into whole shares).
|
2019-07-25 |
| 2019-07-25 | 15312.25 | 未披露 | 定期报告 | 2019-07-24 |
| 2019-05-06 | 14978.82 | 未披露 | 定期报告 | 2019-05-02 |
| 2019-04-25 | 14975.55 | 未披露 | 定期报告 | 2019-04-15 |
| 2019-05-06 | 11931.97 | 未披露 |
更多>>
from July 1, 2018 to March 31, 2019
Stock-based compensation to employees, directors and non-employee consultants
Issuance of common stock under At Market Issuance Sales Agreement, and Open Market Sales Agreement, net of issuance costs of $357
Exercise of options by employees and non-employee consultants
|
2019-03-31 |
| 2019-02-06 | 11685.66 | 未披露 | 定期报告 | 2019-01-31 |
| 2019-02-06 | 11680.94 | 未披露 |
更多>>
from July 1, 2018 to December 31, 2018
Stock-based compensation to employees, directors and non-employee consultants
Issuance of common stock under ATM Agreement, net of issuance costs of $148
Exercise of options by employees and non-employee consultants
|
2018-12-31 |
| 2018-11-07 | 11580.05 | 未披露 | 定期报告 | 2018-11-04 |
| 2018-11-07 | 11464.97 | 未披露 |
更多>>
from July 1, 2018 to September 30, 2018
Stock-based compensation to employees, directors and non-employee consultants
Issuance of common stock under ATM Agreement, net of issuance costs of $27
Exercise of options by employees and non-employee consultants
|
2018-09-30 |
| 2018-09-12 | 11359.55 | 未披露 | 定期报告 | 2018-09-02 |
| 2018-09-12 | 11356.58 | 未披露 |
更多>>
from July 1, 2017 to June 30, 2018
Exercise of options by employees
Stock-based compensation to employees, directors and non-employee consultants
Issuance of common stock under At-The Market (“ATM”) Agreement, net of issuance costs of $174
Issuance of common stock, net of issuance costs of $1,405
Exercise of warrants by investors
|
2018-06-30 |
| 2018-05-09 | 11086.89 | 未披露 | 定期报告 | 2018-05-03 |
| 2018-05-09 | 11086.78 | 未披露 |
更多>>
from July 1, 2017 to March 31, 2018
Exercise of options by employees
Stock-based compensation to employees, directors and non-employee consultants
Issuance of common stock under At-The Market (“ATM”) Agreement, net of issuance costs of $124
Issuance of common stock, net of issuance costs of $1,405
Exercise of warrants by investors
|
2018-03-31 |
| 2018-02-06 | 11009.71 | 未披露 | 定期报告 | 2018-02-01 |
| 2018-02-06 | 10933.76 | 未披露 |
更多>>
from July 1, 2017 to December 31, 2017
Exercise of options by employees
Stock-based compensation to employees, directors and non-employee consultants
Issuance of common stock under At-The Market (“ATM”) Agreement, net of issuance costs of $80
Issuance of common stock, net of issuance costs of $1,405
Exercise of warrants by investors
|
2017-12-31 |
| 2017-11-07 | 10811.19 | 未披露 | 定期报告 | 2017-11-02 |
| 2017-11-07 | 9818.37 | 未披露 |
更多>>
from July 1, 2017 to September 30, 2017
Exercise of options by employees and non-employee consultants
Issuance of common stock under At-The Market (“ATM”) Agreement, net of issuance costs of $80
Exercise of warrants by investors
|
2017-09-30 |
| 2017-09-07 | 9747.37 | 未披露 | 定期报告 | 2017-08-31 |
| 2017-09-07 | 9693.88 | 未披露 |
更多>>
from July 1, 2016 to June 30, 2017
Exercise of options by employees and non-employee consultants
Stock-based compensation to employees, directors and non-employee consultants
Issuance of common stock and warrants related to January 2017 offering, net of issuance costs of $1,532
|
2017-06-30 |
| 2017-05-08 | 9633.12 | 未披露 | 定期报告 | 2017-05-03 |
| 2017-05-08 | 9617.19 | 未披露 |
更多>>
from July 1, 2016 to March 31, 2017
Exercise of options by employees and non-employee consultants
Stock-based compensation to employees, directors and non employee consultants
Issuance of common stock and warrants related to January 2017 offering, net of issuance costs of $1,532
|
2017-03-31 |
| 2017-03-30 | 9617.19 | 未披露 | 定期报告 | 2017-03-29 |
| 2017-02-08 | 9606.59 | 未披露 | 定期报告 | 2017-02-02 |
| 2017-02-08 | 8130.60 | 未披露 |
更多>>
From July 1, 2016 to December 31, 2016
Exercise of options by employees
Stock-based compensation to employees, directors and non-employee consultants
|
2016-12-31 |
| 2016-11-07 | 8102.01 | 未披露 | 定期报告 | 2016-11-02 |
| 2016-11-07 | 8078.02 | 未披露 |
更多>>
From July 1, 2016 to September 30, 2016
Exercise of options by employees
Stock-based compensation to employees, directors and non-employee consultants
|
2016-09-30 |
| 2016-09-07 | 8072.36 | 未披露 | 定期报告 | 2016-08-31 |
| 2016-09-07 | 8026.90 | 未披露 |
更多>>
From July 1, 2015 to June 30, 2016
Exercise of options by employees and non-employee consultants
Stock-based compensation to employees,directors and non-employee consultants
Stock-based compensation to contractor
|
2016-06-30 |
| 2016-05-09 | 8016.16 | 未披露 | 定期报告 | 2016-05-02 |
| 2016-05-09 | 8007.98 | 未披露 |
更多>>
from July 1, 2015 to March 31, 2016
Exercise of options by employees and non-employee consultants
Stock-based compensation to employees, directors and non-employee consultants
Stock-based compensation to contractor
|
2016-03-31 |
| 2016-04-04 | 8000.94 | 未披露 | 定期报告 | 2016-03-01 |
| 2016-02-08 | 7993.39 | 未披露 | 定期报告 | 2016-02-02 |
| 2016-02-08 | 7973.64 | 未披露 |
更多>>
from July 1, 2015 to December 31, 2015
Exercise of options by employees and non-employee consultants
Stock-based compensation to employees, directors and non-employee consultants
|
2015-12-31 |
| 2015-11-05 | 7919.83 | 未披露 |
更多>>
from July 1, 2015 to September 30, 2015
Exercise of options by employees and non-employee consultants
Stock based compensation to employees,directors and non-employee consultants
|
2015-09-30 |
| 2014-05-08 | 6784.95 | 未披露 |
更多>>
from July 1, 2013 to March 31, 2014
Issuance of common stock under ATM Agreement,net of issuance costs of $184
Exercise of options and warrants by employees and consultants
Exercise of warrants by investors and finders
Stock based compensation to employees, directors and non-employee consultants
Issuance of common stock under CHA Agreement
|
2014-03-31 |
Common stock offered 1,200,000 shares by the company
From July 1,2025 to June 30,2026
Exercise of pre-funded warrants
Issuance of common shares, the First Common Warrants and the Second Common Warrants related to the First Offering and the Second Offering (each as defined below), net of issuance costs of $6
Issuance of common shares under the Sales Agreement (as defined below) with Alliance Global Partners, or AGP, net of issuance costs of $59
Share-based compensation to employees, directors, and non-employee consultants
From January 1, 2026 to March 31, 2026
Share-based compensation to employees, directors, and non-employee consultants
Issuance of common shares and Second Common Warrants related to the Second Offering , net of issuance costs of $3 and Issuance of common shares under the Sales Agreement with A.G.P
From October 1, 2025 to December 31, 2025
Share-based compensation to employees, directors, and non-employee consultants
Issuance of common shares and Common Warrants related to the Offering (as defined below), net of issuance costs of $3
Issuance of common shares under a sales agreement with A.G.P, (as defined below), net of issuance costs of $43
Exercise of pre-funded warrants
Common Stock offered 625,000 shares by the company
From July 1, 2025 to September 30, 2025
Share-based compensation to employees, directors, and non-employee consultants
From July 1, 2024 to June 30, 2025
Share-based compensation to employees, directors, and non-employee consultants
Issuance of common shares and warrants related to February 2025 offering, net of issuance costs of $420
Issuance of common shares related to Kokomodo Transaction (defined below), net of issuance costs of $47
From January 1, 2025 to March 31, 2025
Issuance of common shares and warrants, net of issuance costs of $476
Share-based compensation to employees, directors, and non-employee consultants
From October 1, 2024 to December 31, 2024
Share-based compensation to employees, directors, and non-employee consultants
From July 1, 2024 to September 30,2024
Share-based compensation to employees, directors, and non-employee consultants
From July 1, 2023 to June 30, 2024
Share-based compensation to employees, directors, and non-employee consultants
Issuance of common shares under a sales agreement with A.G.P, net of issuance
Round-up of shares due to reverse share split effectuated on April 1, 2024
Pluri Inc. announced that a reverse share split of the Company’s issued and outstanding common shares, par value $0.00001 per share at a ratio of 1-for-8 is expected to be implemented at market open on April 1, 2024.
From October 1, 2023 to December 31, 2023
Share-based compensation to employees, directors, and non-employee consultants
From July 1, 2023 to September 30, 2023
Share-based compensation to employees, directors, and non-employee consultants
From July 1, 2022 to June 30, 2023
Share-based compensation to employees, directors, and non-employee consultants
Issuance of common shares and warrants, net of issuance costs of $445
From January 1, 2023 to March 31, 2023
Share-based compensation to employees, directors, and non-employee consultants
Issuance of common shares and warrants related to December 2022 Private Placement, net of issuance costs of $74
From October 1, 2022 to December 31, 2022
Share-based compensation to employees, directors, and non-employee consultants
Issuance of common stock and warrants related to December 2022 Private Placement, net of issuance costs of $361
From July 1, 2022 to September 30, 2022
Share-based compensation to employees, directors, and non-employee consultants
From July 1, 2021 to June 30, 2022
Share-based compensation to employees, directors and non-employee consultants
Issuance of common shares under Open Market Sales Agreement, net of issuance costs of 380,000
Issuance of common shares related to February 2021 registered direct offering net of issuance costs of 1,923,000
Exercise of options by employees and non-employee consultants
Exercise of warrants by investors
From July 1, 2021 to March 31, 2022
Share-based compensation to employees, directors, and non-employee consultants
From July 1, 2021 to December 31, 2021
Share-based compensation to employees, directors, and non-employee consultants
From July 1, 2021 to September 30, 2021
Share-based compensation to employees, directors, and non-employee consultants
From July 1, 2020 to June 30, 2021
Share-based compensation to employees, directors and non-employee consultants
Issuance of common shares under ATM Agreement, net of issuance costs of $380
Issuance of common shares related to February 2021 registered direct offering net of issuance costs of $1,923
Exercise of options by employees and non-employee consultants
Exercise of warrants by investors
From January 1, 2021 to March 31, 2021
Share-based compensation to employees, directors and non-employee consultants
Issuance of common Share under New ATM Agreement, net of issuance costs of $151
Issuance of common shares related to February 2021 registered direct offering net of issuance costs of 1,923$
1.Common stock offered by the company 4,761,905 shares.
2.Unless otherwise indicated, all information in this prospectus supplement is based on 26,767,362 shares of common stock outstanding as of January 31, 2021.
From October 1,2020 to December 31,2020
Share-based compensation to employees, directors and non-employee consultants
Issuance of common Share under New ATM Agreement, net of issuance costs of $151
Exercise of warrants
Exercise of options by employees and non-employee consultants
From July 1, 2020 to September 30, 2020
Stock-based compensation to employees,directors and non-employee consultant
Issuance of common stock under Open Market Sales Agreement,net of issuance costs of $198
Exercise of options by non-employee consultants
Round up of shares due to reverse stock split effectuated on July 25, 2019
From July 1, 2019 to June 30, 2020
Stock-based compensation to employees, directors and non-employee consultants
Issuance of common stock under Open Market Sales Agreement, net of aggregate issuance costs of $3,573
Issuance of common stock related to May 2020 registered direct offering, net of issuance costs of $99
Exercise of options by employees and non-employee consultants
Exercise of warrants by investors
Round up of shares due to reverse stock split effectuated on July 25, 2019
1.Common stock offered by us 1,587,302 shares
2.based on 16,934,417 shares of common stock outstanding as of December 31, 2019
From January 1, 2020 to March 31, 2020
Stock-based compensation to employees, directors and non-employee consultants
Issuance of common stock under Open Market Sales Agreement, net of issuance costs of $792
from October 1, 2019 to December 31, 2019
Stock-based compensation to employees, directors and non-employee consultants
Issuance of common stock under Open Market Sales Agreement, net of issuance costs of $614
Exercise of options by employees and non-employee consultants
Net loss
from July 1, 2019 to September 30, 2019
Stock-based compensation to employees, directors and non-employee consultants
Issuance of common stock under Open Market Sales Agreement, net of issuance costs of $198
Exercise of options by employees and non-employee consultants
Round up of shares due to reverse stock split effectuated on July 25, 2019
Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced that, its Board of Directors has approved a 1-for-10 reverse split of the Company's (a) authorized shares of common stock; and (b) issued and outstanding shares of common stock. The reverse split will be effective as of market open on July 25, 2019 on Nasdaq. The reverse split will result in each outstanding ten pre-split shares of common stock automatically combining into one new share of common stock without any action on the part of the shareholders. As of July 24, 2019 (immediately prior to the Effective Date), there were 153,122,520 shares of common stock outstanding. As a result of the Reverse Split, there are approximately 15,312,252 shares of common stock outstanding (subject to adjustment due to the effect of rounding fractional shares into whole shares).
from July 1, 2018 to March 31, 2019
Stock-based compensation to employees, directors and non-employee consultants
Issuance of common stock under At Market Issuance Sales Agreement, and Open Market Sales Agreement, net of issuance costs of $357
Exercise of options by employees and non-employee consultants
from July 1, 2018 to December 31, 2018
Stock-based compensation to employees, directors and non-employee consultants
Issuance of common stock under ATM Agreement, net of issuance costs of $148
Exercise of options by employees and non-employee consultants
from July 1, 2018 to September 30, 2018
Stock-based compensation to employees, directors and non-employee consultants
Issuance of common stock under ATM Agreement, net of issuance costs of $27
Exercise of options by employees and non-employee consultants
from July 1, 2017 to June 30, 2018
Exercise of options by employees
Stock-based compensation to employees, directors and non-employee consultants
Issuance of common stock under At-The Market (“ATM”) Agreement, net of issuance costs of $174
Issuance of common stock, net of issuance costs of $1,405
Exercise of warrants by investors
from July 1, 2017 to March 31, 2018
Exercise of options by employees
Stock-based compensation to employees, directors and non-employee consultants
Issuance of common stock under At-The Market (“ATM”) Agreement, net of issuance costs of $124
Issuance of common stock, net of issuance costs of $1,405
Exercise of warrants by investors
from July 1, 2017 to December 31, 2017
Exercise of options by employees
Stock-based compensation to employees, directors and non-employee consultants
Issuance of common stock under At-The Market (“ATM”) Agreement, net of issuance costs of $80
Issuance of common stock, net of issuance costs of $1,405
Exercise of warrants by investors
from July 1, 2017 to September 30, 2017
Exercise of options by employees and non-employee consultants
Issuance of common stock under At-The Market (“ATM”) Agreement, net of issuance costs of $80
Exercise of warrants by investors
from July 1, 2016 to June 30, 2017
Exercise of options by employees and non-employee consultants
Stock-based compensation to employees, directors and non-employee consultants
Issuance of common stock and warrants related to January 2017 offering, net of issuance costs of $1,532
from July 1, 2016 to March 31, 2017
Exercise of options by employees and non-employee consultants
Stock-based compensation to employees, directors and non employee consultants
Issuance of common stock and warrants related to January 2017 offering, net of issuance costs of $1,532
From July 1, 2016 to December 31, 2016
Exercise of options by employees
Stock-based compensation to employees, directors and non-employee consultants
From July 1, 2016 to September 30, 2016
Exercise of options by employees
Stock-based compensation to employees, directors and non-employee consultants
From July 1, 2015 to June 30, 2016
Exercise of options by employees and non-employee consultants
Stock-based compensation to employees,directors and non-employee consultants
Stock-based compensation to contractor
from July 1, 2015 to March 31, 2016
Exercise of options by employees and non-employee consultants
Stock-based compensation to employees, directors and non-employee consultants
Stock-based compensation to contractor
from July 1, 2015 to December 31, 2015
Exercise of options by employees and non-employee consultants
Stock-based compensation to employees, directors and non-employee consultants
from July 1, 2015 to September 30, 2015
Exercise of options by employees and non-employee consultants
Stock based compensation to employees,directors and non-employee consultants
from July 1, 2013 to March 31, 2014
Issuance of common stock under ATM Agreement,net of issuance costs of $184
Exercise of options and warrants by employees and consultants
Exercise of warrants by investors and finders
Stock based compensation to employees, directors and non-employee consultants
Issuance of common stock under CHA Agreement